YN340238 Ruxolitinib phosphate 1092939-17-7

Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities.

YN340170 Baricitinib 1187594-09-7

Baricitinib (LY3009104, INCB028050) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Phase 3...

YN340171 Baricitinib phosphate 1187595-84-1

Baricitinib phosphate is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.

YN340188 Cerdulatinib 1198300-79-6

Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other te...

YN340154 GLPG0634 analog 1206101-20-3

GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.

YN340208 Filgotinib 1206161-97-8

Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.

YN340194 Solcitinib 1206163-45-2

Solcitinib is an inhibitor of JAK1 with an IC50 of 8-9 nM, and shows 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively.

YN340137 Oclacitinib 1208319-26-9

Oclacitinib is a novelJAKinhibitor. Oclacitinib is most potent at inhibitingJAK1(IC50=10nM).

YN340009 FLLL32 1226895-15-3

FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 μM.

YN340120 Gandotinib 1229236-86-5

Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.

YN340222 Ilginatinib hydrochloride 1239358-85-0

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailableJAK2inhibitor, with an IC50 of 0.72nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33nM), JAK3 (IC50, 39nM...

YN340221 Ilginatinib 1239358-86-1

Ilginatinib (NS-018) is a highly active and orally bioavailableJAK2inhibitor, with an IC50 of 0.72nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33nM), JAK3 (IC50, 39nM), and Tyk2 (IC50, 22n...

YN340173 CEP-33779 1257704-57-6

CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.

YN340065 Delgocitinib 1263774-59-9

Delgocitinib (JTE-052) is a specificJAKinhibitor with IC50s of 2.8, 2.6, 13 and 58nM for JAK1, JAK2, JAK3 and Tyk2, respectively.

YN340168 BMS-911543 1271022-90-2

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1?nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.

YN340219 Upadacitinib 1310726-60-3

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200nM) in cellular assa...

YN340197 Itacitinib 1334298-90-6

Itacitinib(INCB39110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.

YN340198 Itacitinib adipate 1334302-63-4

Itacitinib adipate is an orally bioavailable and selectiveJAK1inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.

YN340220 Ilginatinib maleate 1354799-87-3

Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailableJAK2inhibitor, with an IC50 of 0.72nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33nM), JAK3 (IC50, 39nM), and T...

YN340189 Cerdulatinib hydrochloride 1369761-01-2

Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinase...